A detailed history of Bender Robert & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Bender Robert & Associates holds 7,466 shares of ABBV stock, worth $1.45 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
7,466
Previous 8,524 12.41%
Holding current value
$1.45 Million
Previous $1.55 Million 17.53%
% of portfolio
0.28%
Previous 0.36%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

SELL
$159.82 - $182.1 $101,166 - $115,269
-633 Reduced 6.91%
8,524 $1.55 Million
Q4 2023

Jan 31, 2024

SELL
$137.6 - $154.97 $512,835 - $577,573
-3,727 Reduced 28.93%
9,157 $1.42 Million
Q3 2023

Oct 13, 2023

SELL
$133.59 - $154.65 $97,654 - $113,049
-731 Reduced 5.37%
12,884 $1.92 Million
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $2.3 Million - $2.86 Million
-17,349 Reduced 56.03%
13,615 $1.83 Million
Q1 2023

Apr 20, 2023

SELL
$144.61 - $166.54 $21,836 - $25,147
-151 Reduced 0.49%
30,964 $4.93 Million
Q4 2022

Feb 02, 2023

SELL
$138.31 - $165.87 $162,652 - $195,063
-1,176 Reduced 3.64%
31,115 $5.03 Million
Q3 2022

Oct 26, 2022

SELL
$134.21 - $153.93 $10,736 - $12,314
-80 Reduced 0.25%
32,291 $4.33 Million
Q2 2022

Jul 19, 2022

SELL
$137.62 - $174.96 $109,958 - $139,793
-799 Reduced 2.41%
32,371 $4.96 Million
Q1 2022

Apr 14, 2022

SELL
$131.98 - $163.75 $133,299 - $165,387
-1,010 Reduced 2.95%
33,170 $5.38 Million
Q3 2021

Nov 03, 2021

SELL
$106.4 - $120.78 $35,324 - $40,098
-332 Reduced 0.96%
34,180 $3.69 Million
Q2 2021

Jul 16, 2021

SELL
$105.21 - $117.21 $15,781 - $17,581
-150 Reduced 0.43%
34,512 $3.89 Million
Q1 2021

Apr 28, 2021

SELL
$102.3 - $112.62 $511 - $563
-5 Reduced 0.01%
34,662 $3.75 Million
Q4 2020

Jan 29, 2021

BUY
$80.49 - $108.67 $101,819 - $137,467
1,265 Added 3.79%
34,667 $3.72 Million
Q3 2020

Oct 29, 2020

SELL
$85.91 - $100.83 $163,658 - $192,081
-1,905 Reduced 5.4%
33,402 $2.93 Million
Q2 2020

Jul 31, 2020

SELL
$73.37 - $98.18 $131,185 - $175,545
-1,788 Reduced 4.82%
35,307 $3.47 Million
Q1 2020

Apr 21, 2020

SELL
$64.5 - $97.79 $113,842 - $172,599
-1,765 Reduced 4.54%
37,095 $2.83 Million
Q4 2019

Jan 31, 2020

SELL
$72.13 - $90.25 $175,420 - $219,488
-2,432 Reduced 5.89%
38,860 $3.44 Million
Q3 2019

Oct 15, 2019

SELL
$62.98 - $75.72 $111,096 - $133,570
-1,764 Reduced 4.1%
41,292 $3.13 Million
Q2 2019

Jul 30, 2019

SELL
$65.7 - $83.98 $271,275 - $346,753
-4,129 Reduced 8.75%
43,056 $2.92 Million
Q1 2019

Apr 30, 2019

SELL
$77.14 - $90.79 $665,795 - $783,608
-8,631 Reduced 15.46%
47,185 $3.8 Million
Q4 2018

Jan 24, 2019

SELL
$77.85 - $96.01 $68,040 - $83,912
-874 Reduced 1.54%
55,816 $5.15 Million
Q3 2018

Oct 17, 2018

BUY
$88.91 - $98.84 $1,333 - $1,482
15 Added 0.03%
56,690 $5.36 Million
Q2 2018

Jul 27, 2018

BUY
$89.78 - $106.23 $36,450 - $43,129
406 Added 0.72%
56,675 $5.25 Million
Q1 2018

Apr 27, 2018

SELL
$92.01 - $123.21 $161,385 - $216,110
-1,754 Reduced 3.02%
56,269 $5.33 Million
Q4 2017

Jan 19, 2018

SELL
$89.56 - $98.21 $41,914 - $45,962
-468 Reduced 0.8%
58,023 $5.61 Million
Q3 2017

Oct 23, 2017

BUY
$69.85 - $89.22 $4.09 Million - $5.22 Million
58,491
58,491 $5.2 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.